Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Chikungunya · 1 trial · 1 indication
Seroconversion, defined as a 4-fold or greater rise in neutralizing antibody against chikungunya virus, as determined by luciferase-based assay (NT80), induced by PXVX0317. PXVX0317 was administered to prior alphavirus vaccine recipients versus gender- and age-matched controls.
| Arm | Type | Description |
|---|---|---|
| Prior Alpha | EXPERIMENTAL | All study participants received the same Investigational Product according to the same schedule. Participants were prior recipients of experimental alphavirus vaccines. |
| Control: Naïve Alpha | ACTIVE_COMPARATOR | All study participants received the same Investigational Product according to the same schedule. The alphavirus vaccine naïve participants will serve as controls for determining the effect of pre-existing alphavirus immunity on vaccine safety and immunogenicity. |
| Name | Type | Description |
|---|---|---|
| Chikungunya | BIOLOGICAL | Virus Like Particle |
Inclusion Criteria: * Age 18 to 65 years old (inclusive) * For women of childbearing potential, a negative pregnancy test at screening and on vaccination day, practicing highly effective contraception for at least 30 days prior to vaccination, and willing to use a highly effective method of contrac...
Chikungunya is an investigational monoclonal antibody being developed by Emergent BioSolutions Inc. (EBS) for the prevention or treatment of chikungunya, a viral infectious disease. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
Emergent BioSolutions Inc. (ticker: EBS) is developing Chikungunya, a monoclonal antibody for chikungunya. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with the infectious disease.
Chikungunya is in Phase 2 clinical development. It is an investigational monoclonal antibody being studied for chikungunya. The drug is not yet approved and remains in clinical trials to assess its safety and effectiveness.
Chikungunya has one completed Phase 2 clinical trial, NCT03992872, which was an open-label study of an alum-adjuvanted chikungunya virus-like particle vaccine (PXVX0317) in 60 healthy volunteers in the United States. The trial was active-controlled and enrolled adults aged 18 years and older.
Yes, Chikungunya is also known as PXVX0317. In clinical trial NCT03992872, the drug was studied as an alum-adjuvanted chikungunya virus-like particle vaccine. This alternative name may appear in scientific literature and trial registries.